At current levels near $400, UTHR stock trades at 6x trailing revenues —a multiple aligned with its historical average. With ...

United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a ...

(Reuters) -Shares of United Therapeutics surged 37% to an all-time high on Tuesday after its drug Tyvaso significantly improved lung function in patients with a progressive lung condition in a ...

SpliSense, a clinical-stage biotechnology company developing transformative RNA-based therapies for pulmonary diseases, today announced positive results from SPL84-002, its ongoing global Phase 2 ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

United Therapeutics plans to meet with the U.S. FDA before the end of the year to discuss adding idiopathic pulmonary ...

In a study published in Aging on Aug. 8, 2025, researchers at Insilico Medicine unveiled AI-powered models that uncover shared biological pathways between IPF and the aging process, pointing to novel ...

Patients diagnosed with idiopathic pulmonary fibrosis (IPF) and other rare respiratory diseases often face a poor prognosis and limited treatment options. Although the two approved IPF treatments slow ...

Today, 16 leading patient, provider and professional organizations are calling for support and co-sponsorship for the Supplemental Oxygen Access Reform (SOAR) Act (S. 1406/H.R. 2902).

Strategies that combine ferroptosis inhibition with established antifibrotics could ultimately move treatment from slowing progression to truly reversing fibrosis, new research suggests.

To mark Pulmonary Fibrosis Awareness Month, experts have revealed the surprising risk that the lung disease can have on your vision.